Ewing sarcoma partial regression without GvHD by chondromodulin-I/HLA-A*02:01-specific allorestricted T cell receptor transgenic T cells

References

• Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014; 371(16):1507-17; PMID:25317870; https://doi.org/10.1056/NEJMoa1407222
   PubMed Web of Science ®Google Scholar
• von Heyking K, Calzada-Wack J, Göllner S, Neff F, Schmidt O, Hensel T, Schirmer D, Fasan A, Esposito I, Müller-Tidow C, Sorensen PH, Burdach S, Richter GH. The endochondral bone protein CHM1 sustains an undifferentiated, invasive phenotype, promoting lung metastasis in Ewing sarcoma. Mol Oncol. 2017 Mar 20; PMID:28319320; https://doi.org/10.1002/1878-0261.12057
   PubMed Web of Science ®Google Scholar
• Sorensen PH, Lessnick SL, Lopez-Terrada D, Liu XF, Triche TJ, Denny CT. A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG. Nat Genet 1994; 6(2):146-51; PMID:8162068; https://doi.org/10.1038/ng0294-146
   PubMed Web of Science ®Google Scholar
• Thiel U, Wawer A, von Luettichau I, Bender HU, Blaeschke F, Grunewald TG, Steinborn M, Röper B, Bonig H, Klingebiel T et al. Bone marrow involvement identifies a subgroup of advanced Ewing sarcoma patients with fatal outcome irrespective of therapy in contrast to curable patients with multiple bone metastases but unaffected marrow. Oncotarget. 2016 Oct 25; 7(43):70959-70968; PMID:27486822; https://doi.org/10.18632/oncotarget.10938
   PubMed Web of Science ®Google Scholar
• Herzog J, von Klot-Heydenfeldt F, Jabar S, Ranft A, Rossig C, Dirksen U, Van den Brande J, D'Incalci M, von Luettichau I, Grohar PJ et al. Trabectedin followed by irinotecan can stabilize disease in advanced translocation-positive sarcomas with acceptable toxicity. Sarcoma 2016; 2016:7461783; PMID:27843394; https://doi.org/10.1155/2016/7461783
   PubMedGoogle Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373(1):23-34; PMID:26027431; https://doi.org/10.1056/NEJMoa1504030
   PubMed Web of Science ®Google Scholar
• Gubin MM, Artyomov MN, Mardis ER, Schreiber RD. Tumor neoantigens: building a framework for personalized cancer immunotherapy. J Clin Invest 2015; 125(9):3413-21; PMID:26258412; https://doi.org/10.1172/JCI80008
   PubMed Web of Science ®Google Scholar
• Houot R, Schultz LM, Marabelle A, Kohrt H. T-cell-based immunotherapy: adoptive cell transfer and checkpoint inhibition. Cancer Immunol Res 2015; 3(10):1115-22; PMID:26438444; https://doi.org/10.1158/2326-6066.CIR-15-0190
   PubMed Web of Science ®Google Scholar
• Merchant MS, Bernstein D, Amoako M, Baird K, Fleisher TA, Morre M, Steinberg SM, Sabatino M, Stroncek DF, Venkatasan AM et al. Adjuvant immunotherapy to improve outcome in high-risk pediatric sarcomas. Clin Cancer Res 2016; 22(13):3182-91; PMID:26823601; https://doi.org/10.1158/1078-0432.CCR-15-2550
   PubMed Web of Science ®Google Scholar
• Robbins PF, Kassim SH, Tran TL, Crystal JS, Morgan RA, Feldman SA, Yang JC, Dudley ME, Wunderlich JR, Sherry RM et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clin Cancer Res 2015; 21(5):1019-27; PMID:25538264; https://doi.org/10.1158/1078-0432.CCR-14-2708
   PubMed Web of Science ®Google Scholar
• Rossig C. Cellular immunotherapy strategies for Ewing sarcoma. Immunotherapy 2014; 6(5):611-21; PMID:24896629; https://doi.org/10.2217/imt.14.36
   PubMed Web of Science ®Google Scholar
• Orentas RJ, Lee DW, Mackall C. Immunotherapy targets in pediatric cancer. Front Oncol 2012; 2:3; PMID:22645714; http://doi.org/10.3389/fonc.2012.00003
   PubMedGoogle Scholar
• Kolb HJ, Schmid C, Barrett AJ, Schendel DJ. Graft-versus-leukemia reactions in allogeneic chimeras. Blood 2004; 103(3):767-76; PMID:12958064; https://doi.org/10.1182/blood-2003-02-0342
   PubMed Web of Science ®Google Scholar
• Blaeschke F, Thiel U, Kirschner A, Thiede M, Rubio RA, Schirmer D, Kirchner T, Richter  , Mall S, Klar R et al. Human HLA-A*02:01/CHM1+ allo-restricted T cell receptor transgenic CD8+ T Cells specifically inhibit Ewing sarcoma growth in vitro and in vivo. Oncotarget 2016; 7(28):43267-80; PMID:27281613; https://doi.org/10.18632/oncotarget.9218
   PubMed Web of Science ®Google Scholar
• Burdach S, Kolb HJ. The vigor of defense against non-self: potential superiority of allorestricted T cells in immunotherapy of cancer? Front Oncol 2013; 3:100; PMID:23653891; https://doi.org/10.3389/fonc.2013.00100
   PubMedGoogle Scholar
• Kirschner A, Thiede M, Blaeschke F, Richter GH, Gerke JS, Baldauf MC, Grünewald TG, Busch DH, Burdach S, Thiel U. Lysosome-associated membrane glycoprotein 1 predicts fratricide amongst T cell receptor transgenic CD8+ T cells directed against tumor-associated antigens. Oncotarget 2016; 7(35):56584-97; PMID:27447745; https://doi.org/10.18632/oncotarget.10647
   PubMed Web of Science ®Google Scholar
• Schirmer D, Grunewald TG, Klar R, Schmidt O, Wohlleber D, Rubío RA, Uckert W, Thiel U, Bohne F, Busch DH et al. Transgenic antigen-specific, HLA-A*02:01-allo-restricted cytotoxic T cells recognize tumor-associated target antigen STEAP1 with high specificity. Oncoimmunology 2016; 5(6):e1175795; PMID:27471654; https://doi.org/10.1080/2162402X.2016.1175795
   PubMed Web of Science ®Google Scholar
• Staege MS, Hutter C, Neumann I, Foja S, Hattenhorst UE, Hansen G, Afar D, Burdach SE. DNA microarrays reveal relationship of Ewing family tumors to both endothelial and fetal neural crest-derived cells and define novel targets. Cancer Res 2004; 64(22):8213-21; PMID:15548687; https://doi.org/10.1158/0008-5472.CAN-03-4059
   PubMed Web of Science ®Google Scholar
• Thiel U, Pirson S, Muller-Spahn C, Conrad H, Busch DH, Bernhard H, Burdach S, Richter GH. Specific recognition and inhibition of Ewing tumour growth by antigen-specific allo-restricted cytotoxic T cells. Br J Cancer 2011; 104(6):948-56; PMID:21407224; https://doi.org/10.1038/bjc.2011.54
   PubMed Web of Science ®Google Scholar
• McDonald BD, Bunker JJ, Erickson SA, Oh-Hora M, Bendelac A. Crossreactive alphabeta T cell receptors are the predominant targets of thymocyte negative selection. Immunity 2015; 43(5):859-69; PMID:26522985; https://doi.org/10.1016/j.immuni.2015.09.009
   PubMed Web of Science ®Google Scholar
• Gattinoni L, Finkelstein SE, Klebanoff CA, Antony PA, Palmer DC, Spiess PJ, Hwang LN, Yu Z, Wrzesinski C, Heimann DM et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med 2005; 202(7):907-12; PMID:16203864; https://doi.org/10.1084/jem.20050732
   PubMed Web of Science ®Google Scholar
• Rammensee HG, Bevan MJ. Evidence from in vitro studies that tolerance to self-antigens is MHC-restricted. Nature 1984; 308(5961):741-4; PMID:6232464; https://doi.org/10.1038/308741a0
   PubMed Web of Science ®Google Scholar
• Cameron BJ, Gerry AB, Dukes J, Harper JV, Kannan V, Bianchi FC, Grand F, Brewer JE, Gupta M, Plesa G et al. Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci Transl Med 2013; 5(197):197ra03; PMID:23926201; https://doi.org/10.1126/scitranslmed.3006034
   PubMed Web of Science ®Google Scholar
• Richter GH, Plehm S, Fasan A, Rössler S, Unland R, Bennani-Baiti IM, Hotfilder M, Löwel D, von Luettichau I, Mossbrugger I et al. EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation. Proc Natl Acad Sci U S A 2009; 106(13):5324-9; PMID:19289832; https://doi.org/10.1073/pnas.0810759106
   PubMed Web of Science ®Google Scholar
• Felix NJ, Donermeyer DL, Horvath S, Walters JJ, Gross ML, Suri A, Allen PM. Alloreactive T cells respond specifically to multiple distinct peptide-MHC complexes. Nat Immunol 2007; 8(4):388-97; PMID:17322886; https://doi.org/10.1038/ni1446
   PubMed Web of Science ®Google Scholar
• Gardner R, Wu D, Cherian S, Fang M, Hanafi LA, Finney O, Smithers H, Jensen MC, Riddell SR, Maloney DG et al. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Blood 2016; 127(20):2406-10; PMID:26907630; https://doi.org/10.1182/blood-2015-08-665547
   PubMed Web of Science ®Google Scholar
• Mackall CL, Merchant MS, Fry TJ. Immune-based therapies for childhood cancer. Nat Rev Clin Oncol 2014; 11(12):693-703; PMID:25348789; https://doi.org/10.1038/nrclinonc.2014.177
   PubMed Web of Science ®Google Scholar
• Blank CU, Haanen JB, Ribas A, Schumacher TN. CANCER IMMUNOLOGY. The ‘cancer immunogram’. Science 2016; 352(6286):658-60; PMID:27151852; https://doi.org/10.1126/science.aaf2834
   PubMed Web of Science ®Google Scholar
• Crompton BD, Stewart C, Taylor-Weiner A, Alexe G, Kurek KC, Calicchio ML, Kiezun A, Carter SL, Shukla SA, Mehta SS et al. The genomic landscape of pediatric Ewing sarcoma. Cancer Discov 2014; 4(11):1326-41; PMID:25186949; https://doi.org/10.1158/2159-8290.CD-13-1037
   PubMed Web of Science ®Google Scholar
• Klingebiel T, Handgretinger R, Lang P, Bader P, Niethammer D. Haploidentical transplantation for acute lymphoblastic leukemia in childhood. Blood Rev 2004; 18(3):181-92; PMID:15183902; https://doi.org/10.1016/S0268-960X(03)00063-8
   PubMed Web of Science ®Google Scholar